---
created: 2025-04-13
updated: 2025-04-13T10:53
id: E1SO^]WFvs
specialty: pharmaco
specialty_id: 567
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::03-biochem::06-other-topics::01-lysosomal-storage-diseases
  - "source/ak-step1-v11:": 
  - theme/firstaid::01-biochemistry::06-metabolism::39-lysosomal-storage-diseases
  - "source/ak-step1-v11:": 
  - theme/firstaid::01-biochemistry::06-metabolism::39-lysosomal-storage-diseases::sphingolipidoses::gaucher-disease
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::02-metabolism
  - "source/ak-step1-v11:": 
  - theme/physeo::05-biochem::05-metabolism::21-lysosomal-storage-diseases
  - "source/ak-step1-v11:": 
  - theme/physeo::05-biochem::05-metabolism::26-lysosomal-storage-diseases---gaucher-disease
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::07-lysosomal-storage::05-gaucher-disease
  - "source/ak-step1-v11:": 
  - theme/sketchybiochem::02-cell-biology::03-lysosomal-storage-diseases::02-sphingolipidoses-part-2-gaucher-disease,-metachromatic-leukodystrophy,-krabbe-disease
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-stimulants-&-biochemistry-pharmacology::enzyme-replacement-therapy,gene-therapy,and-cystic-fibrosis-therapy
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18421
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Enzyme-replacement therapy for **Gaucher** disease requires **IV recombinant glucocerebrosidase**   * bonus: why IV and how does endocytosis occur?

---

# Answer
enzymes are large proteins that cannot be orally absorved, so ERT must be adm IV   entry into target cells occurs by endocytosis after the RE binds to mannose-6-phosphate receptors on the cell surface